Equities

Chunghwa Chemical Synthesis & Biotech Co Ltd

1762:TAI

Chunghwa Chemical Synthesis & Biotech Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (TWD)42.30
  • Today's Change0.00 / 0.00%
  • Shares traded81.14k
  • 1 Year change-28.31%
  • Beta--
Data delayed at least 20 minutes, as of Sep 23 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy0
Outperform0
Hold1
Sell0
Strong Sell0

Share price forecast in TWD

The one analyst offering a 12 month price target expects Chunghwa Chemical Synthsis&Biotech CoLtd share price to rise to 125.00 in the next year from the last price of 42.30.
High195.5%125.00
Med195.5%125.00
Low195.5%125.00

Earnings history & estimates in TWD

On Aug 06, 2024, Chunghwa Chemical Synthsis&Biotech CoLtd reported 2nd quarter 2024 earnings of 0.270 per share.
The next earnings announcement is expected on Nov 05, 2024.
Average growth rate+35.38%
Chunghwa Chemical Synthsis&Biotech CoLtd reported annual 2023 earnings of 3.39 per share on Mar 11, 2024.
Average growth rate+75.26%
More ▼

Revenue history & estimates in TWD

Chunghwa Chemical Synthesis & Biotech Co., Ltd. had 2nd quarter 2024 revenues of 461.16m. This bettered the 400.00m estimate of the one analyst covering the company. This was 39.75% below the prior year's 2nd quarter results.
Average growth rate+9.30%
Chunghwa Chemical Synthesis & Biotech Co., Ltd. had revenues for the full year 2023 of 2.09bn. This was 1.45% below the prior year's results.
Average growth rate+16.69%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.